30th Sep 2015 09:13
LONDON (Alliance News) - Akers Biosciences Inc on Wednesday said it has signed distribution deals for its heparin-induced thrombocytopenia test in India, Germany, Italy and Scandinavia.
The test is designed to detect a potentially-fatal allergy some have to heparin, the widely-used blood thinner.
No financial details on the distribution deals were disclosed.
"India, Germany, Italy and Scandinavia are all big potential markets for this test as heparin is the primary anticoagulant used in surgeries in each of them," said Chairman Raymond Akers.
Shares in Akers were up 0.9% to 176.50 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
AKR.L